Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Open access
Dong, Shichao, Sun, Chuan · 2022 · Frontiers in Endocrinology

Abstract

Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adverse Event Reporting System (FAERS) data were used to compare the association between different GLP-1RA and AKI in the real world. Methods: FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed. Results: We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively. Conclusions: Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients’ renal function regularly, especially for patients with high kidney risks such as obesity and age.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1032199

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Process of screening cases of acute kidney injury caused by GLP-1 receptor agonists from FAERS database. FAERS, FDA Adverse Event Reporting System; GLP,glucagon-like peptide-1.
Figure 1 Process of screening cases of acute kidney injury caused by GLP-1 receptor agonists from FAERS database. FAERS, FDA Adverse Event Reporting System; GLP,glucagon-like peptide-1.CC BY · PubMed Central
Figure 2 Distribution curve of the onset time of acute kidney injury caused by GLP-1RA.
Figure 2 Distribution curve of the onset time of acute kidney injury caused by GLP-1RA.CC BY · PubMed Central
Figure 3 Mortality and hospitalization rate of acute kidney injury caused by GLP-1RA.
Figure 3 Mortality and hospitalization rate of acute kidney injury caused by GLP-1RA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Jiawei Han, 2001, Data Ming concepts and techniques

Cited by

See all 46

Metadata

Authors
Dong, S., & Sun, C.
Affiliations
  • Second Hospital of Tianjin Medical University (CN)
  • Nanjing Children's Hospital (CN)
Corresponding author
Sun, Chuan
Venue
Frontiers in Endocrinology
Published
2022-12-13
Volume
13
Pages
1032199-1032199
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4312138050
Cited by
37
References
44
Citations by year
2026: 11 · 2025: 16 · 2024: 10
FWCI
4.44
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, acute kidney injury, liraglutide, drug-induced nephrotoxicity, pharmacovigilance, adverse drug reactions, obesity, renal function monitoring, drug safety
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Bayes Theorem, Female, Humans, Male, Middle Aged, Obesity, Acute Kidney Injury, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. https://app.cochat.ai/papers/10.3389/fendo.2022.1032199
The paper
Dong, S., & Sun, C. (2022). Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1032199

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.